foxo4-dri senolytic peptide study 2017 cell alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Development of a novel senolytic
Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Buy FOXO4 DRI Exceptional 99%+ Purity Third Party COA Included Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link
Pay in 4 interest-free payments of $7.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13





